Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.

Mergers
Supernus adds to its CNS portfolio with $400m buyout of Adamas

Supernus Pharmaceuticals, Inc. announced that it will acquire Adamas Pharmaceuticals, Inc. and its slow-growing Parkinson’s disease drug Gocovri on 11 October in a deal that will broaden Supernus’s portfolio in the central nervous system arena and leverage its existing commercial structure to support Gocovri in two Parkinson’s-related indications.

One analyst called it a sensible transaction for both sides, as Supernus will pay $400m up front, with contingent value...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.